Arranon Phase II Data Appear Adequate For Accelerated Approval, FDA Indicates
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Oncologic Drugs Advisory Committee will consider accelerated approval of GSK's antineoplastic agent nelarabine for T-Cell leukemia and lymphoma on Sept. 14.